1. Clinical & Scientific Overview
Povidone-Iodine (5% / 10% Antiseptic Solution, Ointment & Gargle) (TIP-MED-000259, Reference Code [12.27]) is classified under
Dermatological & Topical Antiseptic Preparations (Ch 12) as a Broad-Spectrum Iodophor Antiseptic & Disinfectant.
Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).
Representative Indian Market Examples (Edition 2.7 Ch 12 [12.27], p. 168): Betadine, Wokadine, Cipladine — Strengths & Dosage Forms: Aqueous Solution: 5% w/v, 10% w/v (~1% available iodine); Ointment: 5% w/w, 10% w/w; Surgical Scrub: 7.5% w/v; Mouth Gargle: 1% w/v, 2% w/v; Vaginal Pessary: 200 mg.
Aqueous Solution: 5% w/v, 10% w/v (~1% available iodine); Ointment: 5% w/w, 10% w/w; Surgical Scrub: 7.5% w/v; Mouth Gargle: 1% w/v, 2% w/v; Vaginal Pessary: 200 mg.
3. Mechanism of Action & Pharmacodynamics
Complex of polyvinylpyrrolidone (povidone) and elemental iodine that slowly releases free iodine (I2) -> iodinates and oxidises microbial proteins, nucleotides, and fatty acids across bacteria, fungi, viruses, protozoa, and spores.
4. Therapeutic Indications & Evidence-Supported Uses
- Pre- and post-operative skin antisepsis
- minor wounds, cuts, abrasions, and burns
- infective vaginitis
- oral/pharyngeal mucosal antisepsis (gargle)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adult: Wounds: Apply 5-10% solution or ointment 1-3 times daily. Pre-operative Skin Prep: Apply 10% solution and allow to dry completely for 2-3 minutes (antiseptic action occurs during drying). Gargle (1-2%): Dilute with equal volume of warm water and gargle for 30 seconds up to 4 times daily (DO NOT swallow). • Paediatric: Avoid in neonates <1.5 kg and use sparingly in infants (high percutaneous iodine absorption suppresses neonatal thyroid).
Administration & Meal Timing: See Administration & Counselling below. | Standard clinical schedule per indication.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Avoid application to large open burns (>20% BSA) in renal failure (systemic iodine absorption causes metabolic acidosis and hypernatraemia). • Hepatic: No adjustment required.
Renal: Avoid application to large open burns (>20% BSA) in renal failure (systemic iodine absorption causes metabolic acidosis and hypernatraemia). • Hepatic: No adjustment required.
Renal: Avoid application to large open burns (>20% BSA) in renal failure (systemic iodine absorption causes metabolic acidosis and hypernatraemia). • Hepatic: No adjustment required.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindications: Known iodine hypersensitivity, hyperthyroidism, dermatitis herpetiformis, before/after radioiodine therapy, preterm low-birth-weight neonates. • Precautions: Inactivated partially by heavy blood, pus, and necrotic slough (clean wound with normal saline first); do not pool alcoholic povidone-iodine solution beneath patient in operating theatre (chemical burns and diathermy fire hazard).
Key Clinical Precautions: Renal: Avoid application to large open burns (>20% BSA) in renal failure (systemic iodine absorption causes metabolic acidosis and hypernatraemia). • Hepatic: No adjustment required.
8. Adverse Effects Profile
- Transient local stinging, brown skin/fabric staining (washes off with water).
- Systemic iodine toxicity on extensive burns (metabolic acidosis, renal failure), transient neonatal hypothyroidism (Wolff-Chaikoff effect), contact dermatitis.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Hydrogen peroxide -> mutual inactivation; Silver sulfadiazine / Enzymatic wound debriders -> iodine inactivates enzymes and precipitates silver; Lithium -> additive hypothyroidism if absorbed over large wounds
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: For mouth gargle, spit out completely after 30 seconds; for skin wounds, clean dirt/pus with saline first and allow solution to air-dry.
- Meal & Clock Timing Instruction: See Administration & Counselling below. (Standard clinical schedule per indication.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: OTC / Non-Schedule | NLEM 2022: Yes | Compendia: IP 2026 / NFI 7th Ed 2026 / NLEM 2022 / BNF 90th Ed
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Aqueous Solution: 5% w/v, 10% w/v (~1% available iodine); Ointment: 5% w/w, 10% w/w; Surgical Scrub: 7.5% w/v; Mouth Gargle: 1% w/v, 2% w/v; Vaginal Pessary: 200 mg.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 12 [12.27] (p. 168)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [12.6]-C153 Nadifloxacin — Topical Corticosteroids (Grouped by Potency: Super-Potent Clobeta
- [12.6]-C154 Ketoconazole / Clindamycin Topical Preparations — Topical Corticosteroids (Grouped by Potency: Super-Potent Clobeta
- [12.6]-CMP155 Adapalene 0.1% Gel, Benzoyl Peroxide 2.5%–5% Gel & Luliconazole 1% — Topical Corticosteroids (Grouped by Potency: Super-Potent Clobeta
- [12.23]-CMP168 Gamma Benzene Hexachloride (Lindane 1%) & Oral Ivermectin Scabies Protocol — Topical Synthetic Pyrethroid Ectoparasiticide (Scabicide & Pedicu